Dr. Makker on Combination Approaches in Endometrial Cancer

Video

In Partnership With:

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination approaches garnering interest in endometrial cancer.

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination approaches garnering interest in endometrial cancer.

At the 2018 ASCO Annual Meeting, Makker reported phase Ib/II results on the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) as a treatment for patients with endometrial cancer. Based on preclinical data, both agents have been shown to be effective as single agents and in combination.

As that combination is tested in further trials, Makker anticipates other immunotherapy combinations. Specifically, she predicts that future research will investigate antiangiogenic combinations with immunomodulatory therapy. For example, there is interest in combining cabozantinib (Cabometyx) with immunotherapy. Cabozantinib is an agent that has demonstrated significant activity in patients with renal cell carcinoma. There is also interest in developing drugs that target the PI3/AKT/mTOR pathway in combination with PARP inhibitors, which have shown impressive activity in both breast and ovarian cancer.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,